Yang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yang Zhang has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Anish Thomas
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
90 shared publications - Christopher W. Schultz
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
90 shared publications - Nobuyuki Takahashi
Department of Medical Oncology National Cancer Center Hospital East Kashiwa Japan
85 shared publications - Parth Desai
Department of Hematology & Medical Oncology, Fox Chase Cancer Center, Temple Health , Philadelphia, PA 19140
85 shared publications - Linda Sciuto
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research , Bethesda, Maryland
84 shared publications - Rajesh Kumar
National Cancer Institute 1 Developmental Therapeutics Branch, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
84 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S7 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Supplementary Table 1 Baseline Patient Characteristics Supplementary Table 2 Treatment-Related Adverse Events. Supplementary Table 3 Summary Statistics for PFS, OS, and ORR Across Treatment Arms A, B, and C Supplementary Table 4 Peripheral Immune Cell Phenotypes. Supplementary Table 5 Best Overall Response and Confidence Intervals in the Evaluable Cohort Supplementary Table 6 Clinical Predictors of Hyperprogresson Supplementary Table 7 Univariate and Multivariate Associations With Overall Survival in SCLC in IMpower133
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S9 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Figure S1. Adverse Events Following Treatment with Bintrafusp alfa Figure S2. Progression-free Survival and Overall Survival for All Arms Figure S3. Transcriptional Differences Underlying Clinical Benefit Figure S4. Comparison of HPD rates and survival between bintrafusp alfa and historical topotecan-based controls in relapsed SCLC Figure S5. Comparison of hyperprogressive disease with dual TGF-β/PD-L1 blockade (bintrafusp alfa) across tumor types. Figure S6. Distribution of SCLC Molecular Subtypes and Associated Gene Expression Differences n HPD and non-HPD Patients Figure S7. Functional Effects of TGF-β Signaling and Bintrafusp alfa in SCLC Cell Lines Fig S8. External validation of tumor-intrinsic TGF-β signaling across preclinical and clinical SCLC datasets Figure S9. Increased Frequency of Hyperprogressive Disease with Dual TGF-β/PD-L1 Blockade Compared With PD-1/PD-L1–based Regimens
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Trial Schema; Gating strategy; KEY RESOURCES table
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods-1 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Trial Schema; Gating strategy; KEY RESOURCES table
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Clinical Trial Protocol, IRB amendments and DSMB recommendations
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods-2 from Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Clinical Trial Protocol, IRB amendments and DSMB recommendations
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Stromal immunosuppressive pathways are key modulators of response to immune checkpoint inhibitors, but the tumor-intrinsic consequences of blocking these pathways remain incompletely defined. We conducted a clinical trial of bintrafusp alfa, a bifunctional PD-L1/TGFβ inhibitor, in small cell lung cancer (SCLC). Among 34 evaluable patients, 18% had partial responses, 20% stable disease, and 62% progressive disease; 38% of progressors met the criteria for hyperprogressive disease (HPD). HPD was also observed across other tumor types (n = 450), in higher frequencies with bintrafusp alfa than PD-(L)1 blockade alone. Blood and tumor profiling showed that HPD correlated with systemic immune suppression and elevated TGFβ signaling. Functional studies demonstrated that tumor-intrinsic TGFβ signaling restrains proliferation in a subset of SCLC; pathway blockade triggers hyperproliferation. External validation across cell lines and tumor samples confirmed a tumor-intrinsic TGFβ–high transcriptional state associated with inferior survival. These findings identify a context-dependent, growth-constraining function of TGFβ and support tumor-intrinsic biomarker guidance while targeting stromal immunosuppressive pathways. Significance: This study identifies tumor-intrinsic TGFβ signaling as a context-dependent growth restraint in SCLC and a driver of HPD following TGFβ blockade. A reproducible TGFβ–high mesenchymal state is linked to inferior survival, supporting biomarker-guided use of TGFβ–targeted immunotherapy.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Experimental validation of copy-number of the MYC locus in NCI-H889, DMS-114, NCI-H446 and RA022 patient derived cell lines and number of ecDNA and HSR positive cells in the RA022 patient derived cell lines
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Experimental validation of copy-number of the MYC locus in NCI-H889, DMS-114, NCI-H446 and RA022 patient derived cell lines and number of ecDNA and HSR positive cells in the RA022 patient derived cell lines
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Fusion landscape and ecDNA RLF-MYCL fusions, related to Figure 3.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Fusion landscape and ecDNA RLF-MYCL fusions, related to Figure 3.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Heterogeneity in patient derived samples, related to Figure 5
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Heterogeneity in patient derived samples, related to Figure 5
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Enhancer-enhancer interaction analysis derived from H3K27ac HiChIP in the NCI-H889 and NCI-H524 cell lines. Interaction strength of proximal enhancers was calculated from the “.hic” files generated by the JuiceBox suite.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Enhancer-enhancer interaction analysis derived from H3K27ac HiChIP in the NCI-H889 and NCI-H524 cell lines. Interaction strength of proximal enhancers was calculated from the “.hic” files generated by the JuiceBox suite.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
EcDNA in SCLC, related to Figure 1
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
EcDNA in SCLC, related to Figure 1